"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 1 | 2 |
| 2001 | 4 | 0 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 4 | 5 |
| 2008 | 6 | 5 | 11 |
| 2009 | 3 | 4 | 7 |
| 2010 | 4 | 1 | 5 |
| 2011 | 3 | 2 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 4 | 3 | 7 |
| 2014 | 5 | 2 | 7 |
| 2015 | 5 | 10 | 15 |
| 2016 | 4 | 7 | 11 |
| 2017 | 4 | 4 | 8 |
| 2018 | 5 | 7 | 12 |
| 2019 | 4 | 7 | 11 |
| 2020 | 3 | 4 | 7 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 5 | 5 |
| 2024 | 5 | 5 | 10 |
| 2025 | 3 | 6 | 9 |
| 2026 | 4 | 4 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey. Pediatr Pulmonol. 2026 Aug; 61(8):e71778.
-
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2?-?metastatic breast cancer: a single-institution experience. J Egypt Natl Canc Inst. 2026 Jul 28; 38(1).
-
Pre-treatment of cabozantinib prior to hypofractionated radiotherapy increases immunomodulatory effects and tumor size reduction in a 4T1 breast cancer murine model. Sci Rep. 2026 May 16; 16(1).
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations. Int Urol Nephrol. 2026 Sep; 58(9):3671-3680.
-
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. 2026 Mar 27; 17(1):78-89.
-
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results. Nat Cancer. 2026 Mar; 7(3):424-434.
-
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.
-
The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Selpercatinib Increases Radioactive Iodine Avidity in RET-Fusion Pediatric Thyroid Carcinoma. Pediatrics. 2025 Dec 01; 156(6).